{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:50:09Z","timestamp":1770526209482,"version":"3.49.0"},"reference-count":65,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,10,8]],"date-time":"2002-10-08T00:00:00Z","timestamp":1034035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microscopy Res &amp; Technique"],"published-print":{"date-parts":[[2002,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Assessment of <jats:italic>HER2\/neu<\/jats:italic> oncogene has been used as both a prognostic and predictive marker for breast cancer. However, the choice of the best method to assess the status of <jats:italic>HER2\/neu<\/jats:italic> oncogene in breast cancer tissue remains controversial. A variety of techniques are available to detect <jats:italic>HER2\/neu<\/jats:italic> gene amplification and overexpression. Tissue\u2010based detection methods by immunohistochemistry (IHC) and\/or fluorescence in situ hybridization (FISH) offers a clear advantage over other approaches. FISH is a costly and relatively difficult assay and yet appears to be a better predictor of response to Herceptin\u00ae (Trastuzumab) therapy and patient outcome. IHC is less expensive and is easier to perform; however, it suffers from a high rate of false negativity and positivity as well as inter\u2010observer variability among pathologists. Suggestions have been made to use IHC as a screening procedure followed by confirmation by FISH in selected cases. Considering the importance of an accurate assessment of <jats:italic>HER2\/neu<\/jats:italic> oncogene in selecting therapy, a better alternative may be to use FISH as the primary testing for <jats:italic>HER2\/neu<\/jats:italic> oncogene. Herceptin\u00ae therapy is associated with several side effects and is expensive. Thus, in the long term, it may be more cost\u2010effective to use the FISH procedure and reduce the possibility of under\u2010treatment or over\u2010treatment of breast cancer patients. In addition, assessment of <jats:italic>HER2\/neu<\/jats:italic> oncogene on every newly diagnosed early breast carcinoma may not be necessary. Metastatic lesions, when they occur, can be sampled by fine needle aspiration biopsy or core needle biopsy for assessment of HER2\/Neu status. Microsc. Res. Tech. 59:102\u2013108, 2002. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jemt.10181","type":"journal-article","created":{"date-parts":[[2002,10,9]],"date-time":"2002-10-09T03:56:17Z","timestamp":1034135777000},"page":"102-108","source":"Crossref","is-referenced-by-count":69,"title":["Prognostic and predictive value of <i>HER2\/neu<\/i> oncogene in breast cancer"],"prefix":"10.1002","volume":"59","author":[{"given":"Shahla","family":"Masood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn M.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,10,8]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3012781"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.4.599"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1340"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.497"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.737"},{"key":"e_1_2_1_7_1","first-page":"2825","article-title":"Recombinant humanized antibody (Herceptin\u00ae) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpression human breast cancer xenografts","volume":"58","author":"Baselga J","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1865"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(05)80129-7"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(94)00534-Y"},{"key":"e_1_2_1_11_1","first-page":"373","article-title":"20 year update of the Naples GUN trial of adjuvant breast cancer","volume":"17","author":"Bianco AR","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_12_1","first-page":"4332","article-title":"HER\u20102\/neu amplification predicts poor survival in node\u2010positive breast cancer","volume":"50","author":"Borg A","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(94)90194-5"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2702"},{"key":"e_1_2_1_15_1","first-page":"944","article-title":"Follow\u2010up study of HER\u20102\/neu amplification in primary breast cancer","volume":"51","author":"Clark GM","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2999974"},{"key":"e_1_2_1_18_1","first-page":"18A","article-title":"Prognostic significance of p34cdc2 cyclin dependent kinase and MIB1 overexpression, and HER\u20102\/neu gene amplification detected by fluorescence in\u2010situ hybridization in breast cancer","volume":"11","author":"Depowski PL","year":"1998","journal-title":"Mod Pathol"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2885917"},{"key":"e_1_2_1_20_1","first-page":"7","article-title":"HER\u20102 expression and response to tamoxifen in estrogen receptor\u2010positive breast cancer: a southwest oncology group study","volume":"4","author":"Elledge RM","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_21_1","first-page":"1441","article-title":"Prognostic and predictive relevance of C\u2010erb B2 and ras expression and response to adjuvant therapy in node positive and negative breast cancer","volume":"14","author":"Giai M","year":"1994","journal-title":"Anticancer Res"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1049"},{"key":"e_1_2_1_23_1","unstructured":"HeintzNH LeslieKO RogersLA HowardPL.1990.Amplification of the c\u2010erbB2 oncogene in prognosis of breast adenocarcinoma. Arch Pathol Lab Med.114:160\u2013163."},{"key":"e_1_2_1_24_1","first-page":"471","article-title":"The humanized anti\u2010HER2 antibody rhuMAB HER2 mediates antibody dependent cell\u2010mediated cytotoxicity via Fc\u03b3R III","volume":"37","author":"Hotaling TE","year":"1996","journal-title":"Proc Annu Meet Am Assoc Cancer Res"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.20.7159"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.9.3.1165"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.1983"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1129"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01518520"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.101"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/dc.2840130507"},{"key":"e_1_2_1_32_1","first-page":"215","article-title":"Reproducibility of LSI HER\u20102\/neu SpectrumOrange and CEP 17 SpectrumGreen Dual color DNA probe kit for enumeration of gene amplification in paraffin\u2010embedded specimens: a multicenter clinical validation study","volume":"28","author":"Masood S","year":"1998","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_1_33_1","first-page":"259","article-title":"Assessment of Her\u20102\/neu overexpression in primary breast cancers and their metastatic lesions: and immunohistochemical study","volume":"30","author":"Masood S","year":"2000","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405053301802"},{"key":"e_1_2_1_35_1","first-page":"291","article-title":"The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin Pivotal Trails","volume":"19","author":"Muss RD","year":"2000","journal-title":"Proc ASCO"},{"key":"e_1_2_1_36_1","first-page":"1643","article-title":"Expression of epidermal growth factor receptor and C\u2010erb B2 during the development of tamoxifen resistance in human breast cancer","volume":"3","author":"Newby JC","year":"1997","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(90)90424-J"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.24.1991"},{"key":"e_1_2_1_39_1","first-page":"556","article-title":"Correlation between C\u2010erb B2 amplification and risk of recurrent disease in node\u2010negative breast cancer","volume":"51","author":"Paterson MC","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_1_40_1","first-page":"63","article-title":"Detection and quantitation of HER\u20102\/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization","volume":"13","author":"Pauletti G","year":"1996","journal-title":"Oncogene"},{"key":"e_1_2_1_41_1","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","article-title":"Assessment of methods for tissue\u2010based detection of HER\u20102\/neu alteration in human breast cancer: a direct comparison of FISH and immunohistochemistry","volume":"18","author":"Pauleti G","year":"2000","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_42_1","first-page":"602","article-title":"Antibody dependent cell\u2010mediated cytotoxicity in breast cancer patients in Phase III clinical trials of a humanized anti\u2010HER2 antibody","volume":"38","author":"Pegram MD","year":"1997","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2659"},{"key":"e_1_2_1_44_1","first-page":"41","article-title":"Fluorescence in situ hybridization (FISH) for detection of HER\u20102\/neu amplification in breast cancer: a multicenter portability study","volume":"30","author":"Persons DL","year":"2000","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_1_45_1","first-page":"2771","article-title":"Sensitivity of HER\u20102\/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression","volume":"54","author":"Press MF","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2894"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00665980"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910490109"},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950315)75:6<1320::AID-CNCR2820750614>3.0.CO;2-C"},{"key":"e_1_2_1_50_1","first-page":"26A","article-title":"Multivariate analysis of prognostic factors in lymph node negative breast cancer","volume":"11","author":"Ross JS","year":"1998","journal-title":"Mod Pathol"},{"issue":"1","key":"e_1_2_1_51_1","first-page":"553","article-title":"Her\u20102\/neu (c\u2010erb\u2010B2) gene and protein in breast cancer","volume":"112","author":"Ross JS","year":"1999","journal-title":"Am J Cli Path"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/312513a0"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1936"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.15.1141"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.462"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2470152"},{"key":"e_1_2_1_58_1","first-page":"377","article-title":"Addition of Herceptin (humanized anti\u2010HER\u20102 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled Phase III trial","volume":"17","author":"Slamon D","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00344-4"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64785-2"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1044"},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2281"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198811103191902"},{"key":"e_1_2_1_64_1","first-page":"71a","article-title":"First line, non\u2010hormonal treatment of women with HER2 overexpression metastatic breast cancer with Herceptin (Trastuzumab, humanized anti\u2010HER 2 antibody)","volume":"19","author":"Vogal C","year":"2000","journal-title":"Proc ASCO"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1992.22"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2518"}],"container-title":["Microscopy Research and Technique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjemt.10181","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jemt.10181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:06:16Z","timestamp":1760630776000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jemt.10181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,8]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,10,15]]}},"alternative-id":["10.1002\/jemt.10181"],"URL":"https:\/\/doi.org\/10.1002\/jemt.10181","archive":["Portico"],"relation":{},"ISSN":["1059-910X","1097-0029"],"issn-type":[{"value":"1059-910X","type":"print"},{"value":"1097-0029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,8]]}}}